By John Vandermosten, CFA
TSX:PMN.TO | OTC:ARFXF
Neurodegenerative diseases continue to afflict millions of people worldwide and effective therapies have remained elusive. The best known, most prevalent neurodegenerative pathosis is Alzheimers Disease (AD) but others, such as amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD), are also important diseases that lack an effective therapy. There are no approved disease modifying therapies available for these conditions and only symptomatic treatments are available. However, the latest developments in gene therapy have added another dimension to the fight against neurodegenerative disease with the introduction of intrabodies. These intracellular antibodies have several beneficial characteristics including an ability to bind to misfolded proteins inside the cell and prevent the formation and spread of unwanted aggregates. Combined with output from ProMIS (TSX:PMN.TO) (OTC:ARFXF) computational algorithm, the intrabodies can be very specific, neutralizing only the toxic forms of proteins while sparing normal forms that have important physiological functions.
Antibodies in Neurodegenerative Disease
In all of its forms, neurodegenerative disease is one of the most pressing challenges that modern healthcare faces. It presents detrimental physiological, economic and social effects. Families watch as their loved ones become unable to conduct normal daily tasks and lose the ability to think and control their bodies1. AD, ALS and FTD are all characterized by the accumulation of toxic aggregates that kill neurons. Harnessing the bodys cellular machinery by applying recent advances in viral vectors allows the cell to be used to manufacture the very antibodies that are necessary to stem the spread of neurodegenerative disease.
Antibodies, also known as immunoglobulins, are proteins produced by the body in response to foreign antigens, most commonly bacteria and viruses. Antibodies can be thought of as flags to mark pathogens for sequestering and destruction; the properties of the antibody binding sites determine the antibodys specificity. Antibodies can now be engineered to target specific antigens, a technique currently being exploited across a multitude of indications2. Antigens can include proteins, sugars, or even nucleic acids. The antigens binding site is called the epitope3. Monoclonal antibodies (mAb) can be designed to target the epitope and be recognized by the human immune system.
Shortcomings in Current Approaches
Previous AD-targeted antibody therapies included Roche's gantenerumab, Eli Lilly's solanezumab, and Pfizer's bapineuzumab; these candidates made it to the final stages of clinical trials, but did not progress further. The results showed poor efficacy, highlighting the importance of 1) specificity and 2) identifying the right target.
Of recent interest has been Biogens aducanumab, another amyloid- directed antibody. Aducanumabs clinical trials showed that higher doses aducanumab had statistically significant benefits4. While aducanumab showed that intravenous A-targeted mAb could be effective, modest efficacy, possible dose-limiting edema (ARIA-E) and the necessity of large, frequent dosing indicated there was still more work to be done.
The previous mAb trials have taught invaluable lessons about developing therapies for neurodegenerative diseases, and have elucidated fundamental flaws in intravenously administered mAb. These shortcomings include high cost, frequent dosing, low permeability across the blood-brain barrier, absence of intracellular activity5 and low specificity. A new approach, known as vectorized antibodies, can be used to neutralize misfolded proteins before the leave the cell and dramatically improve the efficacy and safety of neurodegenerative therapies.
Vectorized Intrabodies
Vectorized intrabodies may provide a new treatment pathway that can address the shortcomings of intravenous mAb approaches. To achieve lasting benefit at the minimum dose necessary, viral vectors can be used to deliver the genetic sequence for therapeutic mAb expression in target cells.
A variety of viral vectors have been explored, each with its own advantages. In general, a viral vectors desirability relates to its expression duration, payload capacity and immunogenicity. The most common viral vectors for gene therapy are adenoviruses, adeno-associated viruses (AAV), herpes simplex viruses (HSV), and retroviruses. AAVs and retroviruses can achieve expression in cells that will last for years. The virus with the highest carrying capacity is the HSV at 40kB and the viruses with least immunogenicity are AAVs and retroviruses. Retroviruses integrate their payload into the host genome, causing a permanent modification, but risk mutagenesis. With low immunogenicity and long duration of expression, AAVs have become popular in gene therapy applications6.
Comparison of Viral Vectors for Gene Therapy7
Depending on the target cells, a variety of vector-administration approaches can be used. In the case of the brain, crossing the blood brain barrier is a challenge for viruses and delivery is accomplished either via intracerebral or intraventricular injection. Intracerebral injections allow delivery to a specific part of the brain, while intraventricular exposes the whole brain. Once administered, the AAVs deliver the genetic sequences for mAbs to the target cells and the cells produce the mAb. Intracerebral injection of AAVs has been shown to be safe in humans8.
Apart from the convenience and potential cost savings of lasting mAb expression, by expressing the antibody in the cell (intrabody), targeted proteins can be destroyed before ever leaving the cell. For AD, intrabodies can be used to mark neurotoxic A-oligomers for degradation9. In tauopathy, such as AD and PD, the majority of pathogenic (hyperphosphorylated) tau remains in the cell, and a tau-targeted intrabody can mark hyperphosphorylated tau for degradation, or simply competitively bind tau, minimizing the formation of tau-inclusions10. Externally administered mAb would have limited, if any, efficacy against targets inside cells.
Anti-tau intrabodies have already been studied in mice and the results support neuroprotectivity of tau-targeted immunotherapy11. Gallardo et al. fused ubiquitin, an intracellular degradation signaling molecule, to tau-targeting antibodies, transfected using AAV, and observed substantially decreased intracellular tau levels. While this particular study did not evaluate the mice behaviorally, others have, and tau-directed immunotherapy was shown to elicit behavioral improvements. The therapeutic genre has shown efficacy in mice, and remains to be seen whether it is effective in man.
Specificity and ProMIS Discovery Engine
The importance of specificity has been emphasized by ProMIS in many of its presentations. Many developed antibodies target with a scattershot approach in the hope that enough drug will sufficiently bind to disease causing proteins to have a beneficial effect overall without being diluted by binding non-disease related proteins. ProMIS approach to disease modifying therapy relies not on hope, but rather specificity. Only misfolded toxic species of amyloid-, -synuclein and TDP43 should be bound. Normal forms of these proteins have important physiological functions. Amyloid- aids in synaptic remodeling, -synuclein helps with DNA repair and TDP43 monomer and homodimer play a role in RNA transport. Broadly targeting both toxic and normal forms of proteins will not only miss the intended therapeutic effect but also result in serious side effects that may be as debilitating as the disease itself. To combat the extensive reach of non-specific antibodies, ProMIS employs its proprietary discovery platforms that are able to predict unique epitopes on misfolded toxic forms of proteins implicated in disease. This specificity allows for lower doses of drug to be used and avoids negative outcomes from binding to necessary healthy proteins.
The scientists leading ProMIS have been able to merge chemistry, biology and physics to optimize drug design by employing proprietary algorithms that are able to identify high probability conformations of misfolded proteins. In other words, they have used cutting edge technology to make a better drug.
This type of achievement would not have been possible years ago due to the computational burden required to solve the complex algorithm. However, as technology plays an even larger role in the advancement of medicine and science, ProMIS is in a position to specifically neutralize misfolded proteins in neurodegenerative disease.
Summary
Neurodegenerative diseases persist as a modern healthcare challenge. With the aging population, the number of patients suffering from this affliction will become an increasingly large burden unless we can find an effective solution. There are no disease modifying therapies for the group of neurodegenerative diseases that dominate the space; however, much progress has been made. We now understand that it is the toxic forms of certain proteins that cause many of the neurodegenerative diseases. We also understand that the normal forms of these proteins have beneficial physiological functions that cannot be disrupted without causing negative and damaging side effects. With increased understanding of these pathologies at the protein/cellular level combined with the use of viral vectors to deliver DNA medicines and the ability to identify epitopes specific to the damaging forms of misfolded proteins we have achieved material advancements. This approach provides a new paradigm of therapy that can address neurodegenerative disease even before it leaves the cell.
SUBSCRIBE TO ZACKS SMALL CAP RESEARCHtoreceive our articles and reports emailed directly to you each morning. Please visit ourwebsitefor additional information on Zacks SCR.
DISCLOSURE: Zacks SCR has received compensation from the issuer directly, from an investment manager, or from an investor relations consulting firm, engaged by the issuer, for providing research coverage for a period of no less than one year. Research articles, as seen here, are part of the service Zacks provides and Zacks receives quarterly payments totaling a maximum fee of $40,000 annually for these services. Full Disclaimer HERE.
Read more here:
PMN.TO: Vectorized Antibodies: Cutting Edge Neurodegenerative Therapy - Zacks Small Cap Research
- Stem Cell Therapies: Is This The Future Of Wellness? - Grazia USA - April 20th, 2024
- Signal of Benefit for Stem Cell Therapy in Progressive MS - Medscape - March 7th, 2024
- The Controversies Surrounding Stem Cell Therapy for Autism - The Portugal News - February 24th, 2024
- Benefits of Stem Cell Therapy - News Channel 5 Nashville - February 7th, 2024
- What is Stem Cell Therapy & How It Helps Others - Publicist Paper - January 31st, 2024
- A guide to stem cell therapy in Thailand - Thaiger - January 4th, 2024
- Half of pediatric patients with aHUS benefit from Soliris after... - AHUS News - December 21st, 2023
- Real world analysis on the determinants of survival in primary ... - Nature.com - December 5th, 2023
- The Best Beauty Gifts According To People Who Really Know Skin Care - HuffPost - December 5th, 2023
- The Eyepopping Factory Construction Boom in the US - WOLF STREET - December 3rd, 2023
- Benefit of Neoadjuvant Therapy Illustrated During ESMO Congress ... - Targeted Oncology - December 1st, 2023
- Benefits Outweigh Risks as FDA Inspects CAR-T Cell Therapy ... - Curetoday.com - December 1st, 2023
- Review What Real Cavityn Customers Say About Benefits and Side ... - Seattle Weekly - December 1st, 2023
- 'There is a Scientific Fraud Epidemic' - Slashdot - Slashdot - December 1st, 2023
- 15 Best Hydrating Serums to Soothe Any Skin Type 2023 - Town & Country - December 1st, 2023
- Innovations in Cosmetic Dermatology: A Glimpse into the Future - APN News - December 1st, 2023
- FDA Probes New Cases of Cancer That May Stem From Cancer Cell ... - MedCity News - November 29th, 2023
- Use of plant stem cells in topical formulations on the rise - CosmeticsDesign.com USA - November 29th, 2023
- Stem cell-based treatment controls blood sugar in people with Type ... - EurekAlert - November 29th, 2023
- Biologics Market is projected to grow at a CAGR of 8.5% by 2034: Visiongain - Yahoo Finance - November 29th, 2023
- Scientists devise new technique that can pinpoint the causes and ... - EurekAlert - November 29th, 2023
- Global Advanced Therapy Medicinal Products Market is on the brink ... - PharmiWeb.com - November 29th, 2023
- Introducing Orgavalue - The 2023 EIT InnoStars Awards winner - EU-Startups - November 29th, 2023
- Episode 160: Euan Ashley discusses precision medicine and the ... - IHMC - November 29th, 2023
- Is Phenq Right For You? Review The Facts Before Making a ... - Vashon-Maury Island Beachcomber - November 27th, 2023
- Cavityn Reviews - Does It Work? Cheap Scam or Effective ... - The Daily World - November 25th, 2023
- Trend Hunting With Beautystreams At Cosmoprof Asia 2023 - BeautyMatter - November 25th, 2023
- FDA Considers First CRISPR Gene Editing Treatment That May ... - Slashdot - November 25th, 2023
- How Do Plants Determine Where the Light Is Coming From? - Lab Manager Magazine - November 25th, 2023
- Deaths From Coal Pollution Have Dropped, But Emissions May be ... - Slashdot - November 25th, 2023
- Stem cell-based therapies for stroke in newborns - Cochrane - November 23rd, 2023
- Dr Leslie on Outpatient CAR T-Cell Therapy Programs for ... - OncLive - November 23rd, 2023
- Human Milk-Based Therapy May Be Beneficial in Blood Cancers - Curetoday.com - November 23rd, 2023
- Oncological Horizons: The Synergy of Medical and Surgical ... - Cureus - November 23rd, 2023
- Human and environmental safety of carbon nanotubes across their ... - Nature.com - November 23rd, 2023
- Immix Biopharma to Host KOL Event to Discuss its BCMA-Targeted ... - BioSpace - November 23rd, 2023
- #HearTheMarsdenKids call on NHS London to reconsider cancer ... - Metro.co.uk - November 23rd, 2023
- Diagnosis and Management of Cardiovascular Risk in Patients with ... - Dove Medical Press - November 23rd, 2023
- BioLineRx Reports Third Quarter 2023 Financial Results and ... - PR Newswire - November 21st, 2023
- Why our Award Winners Beauty Box is the ultimate beauty gift (for ... - Yahoo Singapore News - November 21st, 2023
- SightCare Reviews - Is Official Website for Sight Care Legit to Try or ... - Vashon-Maury Island Beachcomber - November 21st, 2023
- Legend Biotech Reports Third Quarter 2023 Results and Recent ... - StreetInsider.com - November 21st, 2023
- Lorenzo's Oil: Can It Really Treat ALD? - Verywell Health - November 19th, 2023
- Doctor Says Living To 120 By End Of Decade Is Possible What's the Secret? - Benzinga - November 19th, 2023
- The week in pharma: action, reaction and insight week to ... - The Pharma Letter - November 19th, 2023
- Race Cannot Be Used To Predict Heart Disease, Scientists Say ... - Slashdot - November 19th, 2023
- SpaceX's Starship Reaches Outer Space Before Intentional ... - Slashdot - November 19th, 2023
- Mesenchymal Stem Cells Market is projected to reach USD 3,319 million by 2030 according to a new research r... - WhaTech Technology and Markets News - November 17th, 2023
- LMRUK: Protecting the next generation through cord blood - Charity Today News - November 17th, 2023
- Anti-aging molecule discovered that extends lifespan - Earth.com - November 17th, 2023
- Montana State researcher envisions living building materials that ... - Montana State University - November 17th, 2023
- OxyHelp Explores the Benefits of Hyperbaric Oxygen Therapy for ... - StreetInsider.com - November 15th, 2023
- Health benefits of bone marrow - Pakistan Observer - November 15th, 2023
- Evolving the standard of care: What is next for functional ... - NeuroNews International - November 15th, 2023
- Affimed Reports Third Quarter 2023 Financial Results and ... - BioSpace - November 15th, 2023
- Meet the World's First Whole-Eye Transplant Recipient - TIME - November 15th, 2023
- Calidi Biotherapeutics Reports Third Quarter 2023 Operating and ... - Business Wire - November 15th, 2023
- 10 Asia-Pacific biotech companies leading innovation in the region - Labiotech.eu - November 15th, 2023
- Fitspresso Reviews (November Update) Natural Ingredients That ... - Bainbridge Island Review - November 15th, 2023
- 2seventy bio Reports Third Quarter Financial Results and Recent ... - Business Wire - November 15th, 2023
- Japan To Create $6.6 Billion Fund To Develop Outer Space Industry ... - Slashdot - November 15th, 2023
- Be The Match, Healthcare Marketing Impact Awards 2023 - Ad Age - November 13th, 2023
- Medicare coverage saves lives. Enrolling shouldn't be this ... - Kevin MD - November 13th, 2023
- Future Ocean Foods: 36 Global Alt-Seafood Startups Form Association To Tackle Overfishing, Microplastics & More - Green Queen Media - November 13th, 2023
- Orchard Therapeutics Reports Third Quarter 2023 Financial Results ... - StreetInsider.com - November 13th, 2023
- Celebrity doctor reveals Hollywoods hidden trend of stem cell antiaging therapies - Longevity.Technology - November 11th, 2023
- Amazon Expands Healthcare Push With One Medical Benefits For ... - Slashdot - November 11th, 2023
- Bene Meat Technologies becomes the first to receive EU approval ... - Pet Food Processing - November 11th, 2023
- FDA Grants Orphan Drug Designation to MAIA Biotechnology for THIO as a Treatment for Glioblastoma - Yahoo Finance - November 11th, 2023
- MaaT Pharma Provides Third Quarter 2023 Business Update and ... - Business Wire - November 11th, 2023
- IN8bio Reports Third Quarter 2023 Financial Results and Provides ... - GlobeNewswire - November 11th, 2023
- Fast Lean Pro Reviews - Overpriced or Optimal Ingredients That ... - Journal of the San Juan Islands - November 11th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - GlobeNewswire - November 11th, 2023
- Worlds first whole-eye and partial face transplant gives Arkansas man new hope - CNN - November 9th, 2023
- Glowing Fingertips And Green Eyes: First-of-Its-Kind Monkey ... - ScienceAlert - November 9th, 2023
- 10 Natural Body Scrubs That Exfoliate And Invigorate My Skin - PINKVILLA - November 9th, 2023
- CRISPR Therapeutics Provides Business Update and Reports Third ... - StreetInsider.com - November 9th, 2023
- Fate Therapeutics Reports Third Quarter 2023 Financial Results and ... - StreetInsider.com - November 9th, 2023
- Sight Care Reviews - Overpriced or Worth the Hype? SightCare Pills ... - Journal of the San Juan Islands - November 9th, 2023
- 6 Amazing Health Benefits Of Giloy (Tinospora cordifolia) - WION - November 9th, 2023
Recent Comments